

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Aurelia Haller

Serial No.: Divisional Application of
Application No. 09/531,375 filed
on March 21, 2000

Filed: On Even Date Herewith

For: RECOMBINANT PARAINFLUENZA
VIRUS EXPRESSION SYSTEMS AND
VACCINES

Confirmation No.: To Be Assigned

Art Unit: To Be Assigned

Examiner: To Be Assigned

Attorney Docket No.: 7682-113-999

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or its Attorneys which are or may be material to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to References AA through AT which are listed on the accompanying List of References Cited by Applicant. Copies of listed references AA-AT are not provided herewith; rather, pursuant to 37 C.F.R. § 1.98(d), Applicants respectfully invite the Examiner's attention to the copies of the References AA-AT, which are present in the file of parent application Serial No. 09/531,375 filed on March 21, 2000.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached List of References Cited by Applicant and make them of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. §1.97(b)(3), since this information disclosure statement is filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013.

Respectfully submitted,

by: *Jacqueline Benn*
Reg No. 43,492

Date: April 14, 2004

Laura A. Coruzzi

Laura A. Coruzzi

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

30,742

(Reg. No.)

Express Mail No.: EV 335 859 668 US

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. 7682-113-999		APPLICATION NO To Be Assigned (Division of Application No. 09/531,375)	
				APPLICANT Aurelia Haller			
				FILING DATE On Even Date Herewith		GROUP To Be Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,869,036	2/9/99	Belshe et al.			

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AB	WO 98/53078	11/26/98	PCT				
	AC	WO 97/34008	9/18/97	PCT (in Spanish w/English abstract)				
	AD	WO 93/14207	7/22/93	PCT				
	AE	WO 89/10405	11/2/89	PCT				
	AF	WO 01/04320 A1	1/20/01					

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
AG	Breker-Klassen et al., 1996, "Comparisons of the F and HN gene sequences of different strains of bovine parainfluenza virus type 3: relationship to phenotype and pathogenicity", Can. J. Vet. Res. 60:228-236
AH	Dimock and Collins, 1993, "Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3", J. Virol. 67:2772-2778
AI	Durbin et al., 1997, "Recovery of infectious parainfluenza virus type 3 from cDNA", Virol. 235:323-332
AJ	Karron et al., 1996, "Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two - to six-month-old infants", Pediatr. Infect. Dis. J. 15:650-654
AK	Klippmark et al., 1990, "Antigenic variation of human and bovine parainfluenza virus type 3 strains", J. Gen. Virol. 71:1577-1580
AL	Palese et al., 1996, "Negative-strand RNA viruses: genetic engineering and applications", Proc. Natl. Acad. Sci. USA 93:11354-11358
AM	Shibuta et al., 1979, "Characterization of bovine parainfluenza virus type 3", Microbiol. Immunol. 23:617-628

	AN	Tao et al., 1999, "A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge", Vaccine 17:1100-1108
	AO	Tao et al., 1998, "Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1", J. Virol. 72:2955-2961
	AP	Karron et al., 1995, "A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children", J. of Infect. Diseases 171: 1107-14
	AQ	Skiadopoulos et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol. 1998 Mar;72(3):1762-8
	AR	Haller, et al., (2000) "Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine Vector", J. Virology 74(24):11626-11635
	AS	Schmidt et al. Journal of Virology, Oct. 2000, Vol. 74, No. 19, pp. 8922-8929.
	AT	Skiadopoulos et al. Journal of Virology, Nov. 2001, Vol. 75, No. 21, pp. 10498-10504.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	